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Introduction: 
The topic of the research paper is viz. the systematic study of the 
pharmaceutical industry of India which is threatened, due to the new controls brought 
by rules and regulations of the WTO region, especially regarding tariff policies, 
TRIPS (Trade Related Intellectual Property Rights), opening of Indian domestic 
market to foreign multinationals by adopting liberalization, maintenance of 
professional standards of business ethics, obtaining the world class quality approvals 
and accreditions for Indian pharmaceutical exports, adoption of 'product patents' in 
addition to 'process patents and restrictions on  unauthorised imitations etc. Till 1995 
Indian Pharmaceutical industry was governed by IPL (Indian Patent Laws) and laws 
controlling the production and distribution practices. After getting the membership of 
the World Trade Organization, which has become the apex international permanent 
body for reorganising and smoothening the World Trade and for bringing ideal 
International order in the global trade ethics by making the necessary controls 
mandatory on the part of the member countries, Indian Pharma industry is facing new 
difficulties and challenges.  
Indian pharmaceutical industry was indirectly and remotely governed by the 
rules and regulations of GATT since 1948 onwards. But there was a sort of lenient 
and soft approach of the GATT which used to revise and reframe its rules from time 
to time, per every new round of GATT conferences. As a result there was relatively 
much more freedom to Indian pharmaceutical industries to grow of their own. 
Especially after 1970s, Indian pharma industry made a very rapid and amazingly 
qualitative progress due to the intrinsic strength of cheaper scientific manpower, 
patronizing policies of the government the excellent competency of Indian 
manufactures in the field of bulk drugs and generic drugs and especially in cost 
effective production process by skills of processes and of reengineering of World 
Class Brands. 
Till 1970, India had only 2257 pharmaceutical units. Their number rose to 
5156 (more than double) by 1980s, and by 1990s, their number shot up to 16000 
units. By the end of the 20th Century India had small, medium and large 
pharmaceutical units together totaling more than 20,000. Thus there has been 10 fold 
progress in the number of industrial units, only during last 30 years. 
Indian pharmaceutical industry employed only about 2 lakh employees in 
1970s. At present it has created employment to more than 30 lakh employees. Indian 
pharmaceutical industry provides drugs and medicines of competitive quality at very 
low prices compared to those of advanced countries and dominates domestic trade by 
about 85 to 90 percent. 
India has achieved the Fourth Global Rank in terms of volume of generic 
market, next to US, Japan and Germany. 
Indian Pharmaceutical industry contributes as a 'net foreign exchange earner' 
by exporting drugs worth Rs. 14000 crores in 2003 as against India's pharma imports 
worth Rs. 4000 crores only. 
It has not only multiplied its Exchange earnings by 20 times in last 3 decades 
but it has captured the global market by penetrating in new markets of 65 countries in 
general and markets of US, European Union China and Brazil in particular. 
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Problem emerged from WTO membership 
Against this background of India's rapid progress of the pharmaceutical industry, 
when India had to accept the membership of WTO; there were partly legitimate and 
partly exaggerated fears in he concessed quarters of captains of pharmaceutical 
industry, economists, policy makers, elected law makers from different  political 
parties and the general public 
1) Since pharmaceutical industry per se is 'capital intensive' due to requirements 
of huge fund allocations for activities of R & D. Indian pharmaceutical 
industries due to their capital deficiency, will be unable to survive in the 
environment of open business competition. 
2) Due to the acceptance of 'patent rights' and the monopoly of MNCs in Global 
pharmaceutical market, Indian consumers will have to pay exhorbitant prices 
to foreign companies. Indian Drug manufacturers Association (IDMA) 
protested that 'prices of all medicines will rise by 5 to 20 times (!) as a 
consequence of the acceptance of TRIPS and WTO dictates. 
3) The general opinion was that acceptance of WTO region will lead to 'country's 
sell out to foreign multinationals' and causing agony to Indian patients by 
compelling them to be parties of this total sell out'. 
Reason for Choosing the topic  
Due to the controversial nature of the burning topic of alleged 'threats to Indian 
pharmaceutical industry due to membership of WTO', this research was motivated to 
conduct an objective and unbiased academic research based on the actual facts and 
figures of this vital issue of public interest. 
Since 1995 onwards, the researcher continued his study and gather the secondary data 
essential for the methodological study. In the meanwhile, India's process patent 
practices, were officially permitted till the year 2005 because the moratorium of the 
years was granted by WTO for official acceptance of 'product patent region' which 
was to commence in India from 2005 onwards. 
The researcher therefore decided to fix the transitional period of ten years of 1993 to 
2003 for objectively examining the perceived impact of WTO region on Indian 
pharmaceutical industry in the areas of viability and sustainability of Indian pharma 
industry, export earnings of pharma industry, employment levels, price levels of drugs 
and medicines in the domestic market, and general prospects of the Indian 
pharmaceutical industry. 
The last but not the least, is that there are very few research studies done for the Ph.D. 
Degree, in Indian Universities in general and there is almost not a single research 
thesis so far to the Management faculty of the Pune University. 
Especially during 1993 upto 1997, since the publication of the proposed draft of the 
Secretary General of GATT Mr. Dunkal a national level debate had reached to very 
intensely agitative and harsh nature about the dilemma viz. whether to joint WTO or 
not and the consensus of the political and even economic opinion was not in favour of 
accepting WTO regime, which according to the antagonists, was certainly detrimental 
to the budding and prospering Indian pharmaceutical industry. The Swadeshi Lobby 
of the BJP and its allies the leftist lobby of the ruling Congress and its allies from the 
so called third front who were ideologically opposed to the entry of multinational 
giants, the three communist parties including CPI, CPM and forward block and the 
captains of big Indian pharmaceutical companies, as well as the small scale drug 
manufacturers who had become nervous due to the threats of the competition from 
global pharma giants, and finally journalists of national and regional newspapers, all 
had recorded their opposition to the acceptance of the WTO region. This nation wide 
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debate continued for a long time, even after India had formally obtained the formal 
membership of WTO. 
The gist of the arguments against the WTO membership can be summed as: 
1) Indian pharma industry in general and small 20 thousand units in particular 
will be totally crashed, destroyed and shattered due to their weakness to stand 
against the formidable competitive threat of the global MNCs. 
2) Due to the Norms and Conditions regarding the proven quality of the durg and 
hyperstrict conditions of US's Food and Drug Administration about Good 
Manufacturing Practices (GMP), Indian Pharmaceutical experts will be 
severely affected which will cause and set back to foreign exchange earnings 
of Indian pharma companies. 
3) Due to the removal or reduction of import tariffs, foreign drugs will become 
cheaper and affordable to the middle class population of India and Indian 
small companies will also lose even their domestic markets. 
Title of the proposed research 
In consultation with my guide, while preparing the synopsis and broad outline of the 
proposed research, it was decided that the title of the research should be short, precise, 
specific and logically sharp. Bearing with that view, following title was accepted as a 
final one. 
It is as follows : 
"The impact of WTO on Trading in Pharmaceutical Products in India (1993 - 2003)" 
The title itself identifies and defines the paradigms of the scope and coverage of the 
study, which consists of following areas. 
a) Prevailing strength and weakness of Indian pharmaceutical industry in the 
total global industry. 
b) The nature of various strict and rigorous controls of the apex authority to 
supervise, monitor and maintain the order of ethics and discipline in the global 
trade and their direct and indirect impact on the prospects of Indian 
pharmaceutical industry. 
c) The objective assessment of India's Gains and Losses, of opportunities and 
threats produced by the acceptance of the WTO region. 
d) A data based and quantitative exercise of examining the truth and the 
substance of arguments based on perceived fears and biased prejudices, as 
well as, emotive overreactions which were against WTO region, vis-a-vis, the 
facts and actual evidence of the 'state of affairs' concerning particularly with 
Indian pharmaceutical industry. 
e) A broad and exhaustive survey of pros and cons of WTO region affecting 
Indian Pharmaceutical Business. 
f) The study to be logically confined to the period of 1993-2003 being the period 
of transition and transformation from 'Process patent region' to 'Product patent 
region'. 
Methodology and the sources of data 
The entire study will obviously be based on the secondary data and the empirical 
evidence. The data will be systematically processed, analysed and interpreted so as to 
derive the logical findings of the research. 
 
Since pharmaceutical industry in India has no independent status since it has been 
clubbed as a part of the chemical industry; it is very difficult to obtain the separate 
data of the same. Probably due to that reason, very few researches have been 
conducted in this area, so far. 
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The main data sources are following - 
1) The U. N. Handbook of statistics 
2) The World Development Report published by World Bank. 
3) The data published regarding World's Exports and Imports by the U.N. 
4) WTO reports, periodical publications. 
5) The statistics published by 'the World's Chemical Market'. 
6) World Health organisation - reports (WHO) 
7) General Agreement on trades and tariffs - GATT - Reports. 
8) Economic survey - published by Ministry of Finance Govt. of India. 
9) Scrip's year books. 
10) Confederation of Indian Industries - Publications, reports, data 
11) Federation of Indian chamber of commerce and industries - reports. 
12) Centre for monitoring Indian Economy (CMIE) Monthly and special issues. 
13) Sector profile of the pharma industry - SOMO 
14) Fortune 500 companies - status report 
15) Saket pharma handbooks of 1995 to 2007. 
16) Statistical outline of India (Tata E. R. Publication) 
17) Reports of the Drugs Price Control Committees. 
18) India's legislation regarding Drug Controls, Patents, Prices etc. 
19) Indian Drug Manufacturer's Association, Reports and Representations  
20) Essential reference books, research papers, enquiry committees, journals and 
periodicals ministry of chemicals and pharmaceutical Govt. of India, Annual 
reports etc.  
Hypothesis 
Hypothesis which is to be tested and verified by the analytical data has been 
categorically stated as follows. viz. "The overall impact of WTO region on the 
business prospects of Indian Pharmaceutical Industry has been much more 
benevolent, rather than malignant, since it has factually created for more trade 
opportunities and benefits rather than the threats and disasters causing serious 
damages to same. 
Objectives of the Research 
i) To examine the profile of World's Pharmaceutical Industry and its trade with 
reference to the dominant players who have sizeable shares in total global 
market. To find out the dominant regions which make large purchases of drugs 
and medicines by their respective purchasing powers and the health 
awareness. To study the trends in the growth of the pharmaceutical trade in the 
World in the period of the 'cold war' and the current decade of the 21st 
century. 
ii) To study in details the growth and progress of the pharmaceutical industry in 
India during pre-independence and post independence decades. To account for 
the total value added by the Indian pharmaceutical industry, the shares of 
foreign exchange earnings as well as the earnings from the domestic market. 
To identify the dominant pharma companies and their respective shares in the 
total pharmaceutical business. To examine the trends of its growth especially 
is post 1960s as well as during the decade of economic reforms and the 
membership of WTO. To identify the areas and prospective potential for the 
progress of Indian Pharmaceutical industries, after adopting the WTO region. 
To study the composition of India's exports and imports of pharmaceuticals in 
post 1980s. 
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iii) To examine the developments in Indian Pharma Policies, Indian laws 
governing the practices of the industry and the trade, various controls, quality 
and pricing policies, patent acts, rules and regulations, changes in Indian 
legislation and controls during the membership of the WTO. 
iv) To study the impact of direct and indirect controls of GATT, WTO and WHO 
on Indian Pharma business. 
v) To make exhaustive study of the positive and negative impact of TRIPs, on 
India's pharmaceutical business. 
vi) To make objective assessment of the pros and cons, advantages and 
disadvantages, benefits and losses and the opportunities and threats caused by 
the new region of the WTO. 
The importance of this study 
The pharmaceutical industry has remained a grey area in academic research especially 
in the disciplines of Economic Commerce and the Management science. It has 
emerged as the fourth Foreign Exchange Earner next to Textiles, Gems and Jewellery 
and Software and IT services. Indian pharmaceutical industry is one of the fastest 
growing sector especially during last 3 decades having average rate of growth of not 
less than 15 percent. Due to the availability of highly skilled scientific manpower, 
innovative and adoptive efficiency and comparative cost advantage, it is going to 
emerge as one of the Top TEN leading industries of the World in next 2 decades. This 
research therefore is appropriate and its timing is so perfect that it will enlighten the 
people engaged in Indian pharma industry such as the policy makers, the government 
the academics from pharmacy, biotechnology, economic and management, as well as 
the general public. 
The study will explore a number of areas which have been neglected in the 
mainstream of the academic research and will make an original contribution which 
will be useful to the practical use and benefit due to its applied nature.  
Overview of global pharma sales 
1) The overall world pharma sales by 2003-04 stood at US $ 320 billion, which 
increased upto more than $ 500 billion by 2007-08. More than 84 percent 
share of the total global pharma trade belongs to the products free from patent 
protections. As per the WTO directives, more than US $ 8 billion worth of 
pharma products will go off 'patent restrictions' by 2005. 
2) The shares of global pharmaceutical trade are as follows - 
 
a) U.S. 33% 
b) E.U. 26% 
c) Japan 21% 
d) The rest of the world 20% 
 Total 100% 
 
 
N.B. The dominating players in the global pharma trade are U.S., EU and Japan. 
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3) Annual per capita drug expenditure of selected countries. 
 
Country U.S $  Country U.S $ 
Japan 412  Turkey 21 
Germany 222  Morocco 17 
US 191  Brazil 16 
Canada 124  Philipines 11 
UK 97  China 7 
Costa Rica 37  India 5 
Chile 30  Bangladesh 2 
Mexico 28  Mozambique 2 
N.B. For expanding and penetrating into the World's buyer's market, India will have 
to win the markets of Japan, Germany, US, Canada, UK, Mexico, Brazil as per 
strategic planning.1 
 
4) In the context of the profile of the global pharma trade, Indian Pharma 
companies have three options viz.  
i)  To try to compete with the multinationals by producing their own 
patented inventions. 
ii)  To produce patented drugs under license with collaborations of the 
parent MNCs. 
iii)  To make generics which are free from patent restrictions because of 
the comparative cost advantage and larger share of the global market. 
SWOT Analysis of India vis - a - vis global countries 
A) Strengths of Indian pharma industry 
1) Cost competitiveness 2) Well developed industry with strong 
manufacturing base 3) Access to pool of highly trained scientists  4) Strong 
marketing and distribution network  5) Rich biodiversity  6) Competencies in 
chemistry and process development. 
B) Weakness 
1) Low investments in innovative research and development - General 
Deficiency in Capital Resources 2) Lack of resources to compete with MNCs 
for New Drug Discovery Research and to commercialize molecules on a 
worldwide basis. 3) Lack of strong linkages between industry and academia. 
4) Low medical expenditure per capita, therefore chronic limitations on 
domestic market 5) Production of spurious, low quality drugs, fake 
immitations etc. tarnish the image of the industry at home and abroad. 6) 
Shortage of medicines containing psychotropic substances 
C) Opportunities 
1) Significant export potential global market  2) Licensing deals with MNCs  
3) Marketing alliances to produce and sell MNC products at home and abroad  
4) Contract manufacturing and outsourcing contracts gained by Indian 
companies  5) Potential for developing India as a centre for international 
clinical trials  6) Supply of 'generic drugs' to developed and developing 
markets. 
D) Threats 
1) Product patent regime and domination of MNCs 2) Restrictions on animal 
testing in India 3) Drug price control order puts unrealistic ceilings on 'product 
                                                        
1 Pradeep Misra - Indian pharma reference guide 2005-06 section 1-8 
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prices' and profitability 4) Lowering of tariff protection due to dictates of 
WTO  5) The new MRP based excise duty regime has destroyed "small 
pharma firms" in the state of A.P. and Maharashtra, which were involved in 
contract manufacturing.2 
 
Table  : Word Dev. Indicators – The World Bank – April 2006 
Selected 
countries 
Researchers 
in R&D per 
millian 
people 
1996-04 
Sci. 
Tech. 
Jounals 
2001 
Hightech 
Exports 
$ bn   of  
manufacture 
Patent 
Application 
filed 
Trademark 
Appl. filed 
% of G 
D P 
spent on 
R &D 
Australia 3670 14788 312 14 96434 26831 1.63 
Canada 3597 22626 25.6 bn 14 102418 19664 1.94 
China 663 20978 161.6 30 140910 3210340 1.31 
France 3213 31317 64.8 19 160056 58035 2.19 
Germany 3261 43623 131.8 17 230066 53817 2.5 
India 119 11076 2.8 5 91704 --- 0.8 
Japan 5287 57420 124.0 24 371495 100145 3.15 
Koreas 3187 11037 75.7 33 76860 126836 2.6 
Malaysia 299 494 52.8 55 782 ----- 0.6 
Pakistan 86 282 150mn 1 58 ----- 0.2 
Russia 3319 15846 3.4 9 24049 26279 1.2 
U. K. 2706 47660 64.2 24 251239 51399 1.8 
U. S. 4484 200870 216.0 32 183398 * 2.6 
 
Source – Global Competative Report   
The figure in the table reveal very interesting things 
1) U.S. is undoubtedly the World's leader in R & D activities, the number of 
scientific & technical journals publisher, high-tech exports, highest percentage 
of manufacturing in total exports, the number of patents application filed per 
year, the no. Of Trademark application s filled and highest percentage of GDP 
spent on healthcare.  
(The No of Journals: 2lakh, The No. of patents about: 2lakh No. of trademark 
applications: about 2 lakh, the No. of Researcher per million: about 4500.)  
As a result of this strength, U.S. leads & influences the global pharmaceutical 
business.  
2) Japan is equally strong in these aspects; It has more than 5000 researchers 
available per million of population, The No. of patent applications filled by 
Japan is the highest of the world being about 4 lakh. Japan spends the World's 
highest percentage of GDP on Research. 
3) The third influential country is U. K. having 47000 scientific journals, about 
2.5 lakh patent applications & 1/2 lakh trademark application. Fourth Rank 
goes to Germany having more than 3000/ vermilion researchers, about 'l'2 lakh 
journals, 2 lakh patent application.  
4) China is making tremendous progress in recent years having 11/2 lakh patent 
applications & 3.2 lakh trade mark applications. Korea also is picking up by 
about 1 lakh patent & 1.2 lakh trade mark applications.  
                                                        
2 FICCI - Indian pharma industry - report for NMCC - pages 1 to 12 
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5) Both Australia & Canada have large number of researcher (about 3500/ 1 
million people), the large no. of scientific journals being about 20000, 1 lakh 
patent application & about 2000 trademark applications.  
 
Summing up, U. S., Japan, Germany, France, U.K., Russia, China, Australia, Canada, 
Korea & India are among the leading nations in pharmaceutical business of the world.  
As per as high-tech export earnings p.a. care concerned. Following countries have 
their ranks in descending order viz.l) U.S. (216 bn) 2) China (161 bn), 3) Japan $ 64 
bn. Compared to them, India Pakistan are on the lowest ranking order.  
Pharma Education And Training : 
The National Institute of Pharmaceutical Education and Research (NIPER) has been 
set up by the Government of India as an institute of "national importance" to achieve 
excellence in pharmaceutical sciences and technologies, education and training. 
Through this institute, Government’s endeavor will be to upgrade the standards of 
pharmacy education and R&D. Besides tackling problems of human resources 
development for academia and the indigenous pharmaceutical industry, the institute 
will make efforts to maximize collaborative research with the industry and other 
technical institutes in the area of drug discovery and pharma technology development. 
 
Intellectual Property Rights (IPR) 
The Indian regulatory system is nowhere close to the sophisticated regulatory systems 
of developed nations, and because the legislation is much weaker than internationally 
accepted norms, the entry barrier for developed nations into the Indian market is 
practically non-existent. 
By joining the WTO, India has committed itself to alter its existing Patent Act to offer 
wider and stronger protection to intellectual property rights of any member nation. 
The time frame for complete transition to the new law allowed by the WTO is ten 
years. So far, the new law, although drafted and placed before the Indian Parliament, 
had been mired in controversy and inaction because most of the legislators were 
opposed to it in its present form, regardless of their political affiliation.  
As per the April 1998 agreement reached between the U.S. and India at Geneva, a 
patent amendment bill has finally been passed by India's lower house of3 parliament, 
enabling the country to meet the WTO’s April deadline for complying with TRIPs. 
The bill replaces the ordinance issued in February after the lower house failed to pass 
a patent amendment bill before the end of the parliamentary session. The bill gives 
companies exclusive marking rights in India for patented pharmaceutical products and 
provides a legal framework for the "mailbox" provisions for new product patent 
applications, as required under TRIPs.  
The introduction of full product patent protection now looks likely to be deferred until 
2005, the latest date allowed under the TRIPs provisional arrangements. Although 
India has now taken the first steps towards strengthening its intellectual property laws 
in line with WTO agreements, debates within the country show few signs of arrising 
at consensus. Opinion was sharply polarized between those who would like to see 
India adopt full product patent protection as soon as possible, with no strings attached, 
and those who argue that it should be delayed for as long as possible and that 
measures such as compulsory licensing should be retained to protect the domestic 
pharmaceutical industry. For the pharmaceutical industry, the new law, whatever be 
its final form, signifies a transition to product, rather than process patents. There is a 
                                                        
3 Loksabha - Patent Amendment Bill - 1998 
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very strong demand from developed countries that the importation of a patented 
product be considered on par with working the patent in the importing country, and 
generally to restrict compulsory licensing of the patent on this ground.  
This means that Indian companies would no longer be in a position to introduce new 
products if they are not the original innovators of those products. However, they 
would enjoy the same protection in all member countries for new products that they 
develop.  
Although this regression seems to be totally unfair from the point of view of Indian 
industry, with its limited capabilities with respect to new product development4 
The real impact of this provision for the pharmaceutical industry will, at best be 
marginal over the short to medium term. 
The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) 
provides for minimum norms and standards in respect of the following categories of 
intellectual property rights: -  
1. Copyrights and related rights  
2. Trademarks  
3. Geographical Indications  
4. Industrial Designs  
5. Patents  
6. Lay out designs of integrated circuits 
7. Protection of undisclosed information (trade secrets)  
The Agreement sets out minimum standards to be adopted by the parties, though they 
are free to provide higher standards of protection. A transition period of five years is 
available to all developing countries to give effect to the provisions of the TRIPS 
Agreement. This period ended on 1.1.2000. No transitional period is available, 
however, for grant of national treatment and most-favoured-nation treatment. 
Countries that did not provide product patents in certain areas of technology as on 
1.1.1995, can delay the grant of product patents in those areas for another five years 
i.e. upto 1.1.2005. 
Where a country does not make available patent protection for pharmaceutical and 
agricultural chemical products as on 1.1.1995, they have to provide a means for 
accepting applications for such inventions (mailbox), apply applicable priority rights 
and provide exclusive marketing rights (EMRs) for such products. The EMRs have to 
be provided in India only if a set of conditions have5 been met, i.e. where a patent 
application has been filed after 1.1.1995 by any WTO Member, patent and marketing 
approval granted in that Member country, an application has been filed in the mailbox 
in India and marketing approval obtained in India. The EMR is available for five 
years from grant or till the patent is granted or rejected, whichever is earlier. The 
Patent (Amendment) Act, 1999 was passed in March 1999 to provide for mailbox and 
EMR facility.  
The Direct / Indirect Controls Of WTO, GATT & WHO On Pharma Business 
The information is given about formation of GATT, key elements of GATT 
Agreement, formation of WTO, key factors of WTO Agreement, standards and non-
tariff barriers of trade, tariff reduction and bindings, market access, domestic support, 
SPS measures, TRIPS, agricultural subsidies, and agreement on antidumping 
measures etc. After study of these factors the main objective of WTO to flourish 
globalised trade comes into focus. 
                                                        
4 Ibid 
5 Amendments prepared in Indian  Patent Act  of 1970. Loksabha Bill - 1995 - 96 
VOLUME-I, ISSUE-I                                                                                   ISSN (Online): 2454-8499             
 
INTERNATIONAL RESEARCH JOURNAL OF MULTIDISCIPLINARY STUDIES 
10th  August, 2015  Page 10 
Website: www.irjms.in                                                                 Email: irjms2015@gmail.com 
 
Formation Of GATT. 
In 1944, the international community, which was coming out of the shadow of second 
world war, was emphasizing international co-operation for mutual prosperity and 
peace. In 1945, 23 members including India signed a protocol, which brought into 
existence GATT (General Agreement on Tariffs & Trade) on 1st January 1948, with 
the main objective of bringing order to international trade.  By 1994, the GATT 
membership increased to 136 countries. 
Key Elements Of GATT Agreement: 
1. The Most Favoured Nations (MFN) Clause  
2. Binding commitments 
3. National treatment  
4. Removal of quantitative restrictions. 
5. Transparencies 
 
The MFN Rule provides that the country, which is offered most favourable treatment 
(like reduction in customs duty), should immediately give the same treatment to other 
member countries of GATT. Thus there would be no discrimination among GATT 
members at the hands of one country. 
 
The binding commitments stipulate that the members undertake commitments in 
which they state the maximum level of import duty or other charges or restrictions 
they will apply to import of specific goods.  
 
As regards national treatment the member country cannot discriminate between the 
national product and imported product once the imported product enters the 
boundaries of the country.  Thus the national treatment principle means that the 
protection of domestic product should be given only through action at the frontier like 
levying customs duty etc. Once this protection has been offered and once the foreign 
goods enter the member country these goods are at par with the domestic goods. 
WTO expects removal of quantitative restrictions (QR) if not immediately at least in a 
progressive manner as per the schedule.  According to WTO the QRs function as 
Non-Tariff Barriers and hence protection to domestic products be given through 
customs Tariff.   
As regards transparencies it has to be followed when the governmental agencies 
procure goods and services there should not be any discrimination between domestic 
goods/ services on the one hand and the foreign goods/ services on the other.   
Formation Of WTO    
After over 7 years of negotiations the Uruguay Round multilateral trade negotiations 
were concluded on December 15, 1993 and were formally ratified in April 1994 at 
Marrakesh, Morocco. The WTO Agreement on Agriculture (AOA) was one of the 
many agreements, which were negotiated during the Uruguay Round.  
The implementation of the Agreement on Agriculture started with effect from 
1.1.1995. As per the provisions of the Agreement, the developed countries would 
complete their commitments of reduction of tariffs within 6 years, i.e., by the year 
2000, whereas the commitments of the developing countries would be completed 
within 10 years, i.e., by the year 2004. The least developed countries are not required 
to make any reductions.  
The products which are included within the purview of this agreement are what are 
normally considered as part of agriculture except that it excludes fishery and forestry 
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products as well as rubber, jute, sisal, abaca and coir. The exact product coverage can 
be accessed in the legal text of the agreement. 
Key Factors Of The WTO Agreement 
The WTO Agreement on Agriculture (AOA) contains provisions in 3 broad areas of 
agriculture and trade policy: market access, domestic support and export subsidies.  
Market Access 
Market access refers to the ability of providers of foreign goods and services to sell in 
a given country. For the purposes of market access negotiations in the WTO context, 
tradeable items are subdivided into four groups  agricultural goods, textiles and 
clothing, industrial goods, and services.  
This includes tariffication, tariff reduction and access to opportunities. Tariffication 
means that all non-tariff barriers such as quotas, variable levies, minimum import 
prices, discretionary licensing, state trading measures, voluntary restraint agreements 
etc. need to be abolished and converted into an equivalent tariff. Ordinary tariffs 
including those resulting from their tariffication are to be reduced by developed 
countries an average of 36% with minimum rate of reduction of 15% for each tariff 
item over a 6 year period6. Developing countries are required to reduce tariffs by 24% 
in 10 years. Developing countries as were maintaining Quantitative Restrictions due 
to balance of payment problems, were allowed to offer ceiling bindings instead of 
tariffication. 
Main Findings & conclusion 
1) Compared to 1960s, quality of human life and improvement in health & 
physical fitness, have brought radical changes in longevity and the average life 
expectancy of the global humanity. In 1960, only 41 countries had life 
expectation of 65 to 75 years. By 1990s more than 80 countries of the world 
have average life expectancy increase to 65 to 75 years. Even in the poor & 
backward countries like Asian & Sub-Saharan African countries; the life 
expectancy has been improved to the range of 45 to 55 years. 
2) This great revolution is the outcome of the progress of hygienic and sanitary 
conditions of living mass injections & medicines to treat epidemics & 
infectious diseases had very rapid improvement in the Research & 
Development of effective drugs & medicines supported by medical 
infrastructure, equipment and rise in the number of hospital beds, doctors & 
health workers per capita of country’s population. 
3) Among essential wants of human life,  medicines have equal 
importance like food, water & shelter. The want for medicines is 
statutory and permanent therefore pharmaceutical industry never 
faces serious recession. As the incomes of all countries have been 
rising during 20 th Century (Compared to income level of 19 th 
Century) the overall purchasing power also has been rising and due 
to the spread of education and health awareness, the global demand  
for drugs & medicines, has been very rapidly increasing.  
4) Compared to 19 t h Century, human life has become not vu lnerable to  
diseases like cholera, Malaria, Influeriza,  smallpox, chickenpox, 
typho id, pluracy, T.B, Aneamia etc.,but in 20 t h Century, there is a 
rapid spread of new diseases like Diabetes,  cancer, blood pressure,  
heart attack, paralysis, arthritis, HIV aids etc., in both developed & 
developing countries. However, modern pharmaceutical industry 
                                                        
6 WTO =  
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has taken commendable effort in discovering new life saving drugs,  
which can also effectively cure these serious & complicated 
diseases.  
5) The Pharmaceutical industry has made tremendous progress by its 
R & D in the major advanced economies of U.S., Germany, Japan, 
France, U.K; Switzerland, Thailand, Netherlands and the Giant 
Multinational Companies hare expanded their production & 
marketing activities by collaborations Direct Foreign Investments 
Technology transfer, patent. Sale etc.; which has contributed to a 
great diffusion of medical expertise all over the world. Like other 
developing countries such as China, Brazil etc., India has also 
made tremendous & very rapid progress in manufacturing of 
especially ‘generic drugs’ and has been successful in obtaining 
market for its phrma products even in advanced economies of the 
world. 
6) The ‘Value-added’ contribution of India’s pharmaceutical industry 
in the total national income has been one of the major factors of 
India's national product.  India produces almost all the modern 
medicine at lower comparative costs b y retaining the ‘quality’.  
There is a vast domestic market of 1 billion p lus population,  
available for India’s pharma industry.  
7) Especially during the economic- reform era of post- 1990s; India’  
export earnings per annum are sporadically r ising by average 
incremental percentage of growth of more than 25 o 40 percent,  
Pharmaceutical industry has emerged as one of the biggest foreign 
Exchange earners like Software, automobiles, gems & jewellery,  
marine products, Textiles, readymade garments & basmati r ice! 
With the r ise in biotech; it is quite likely that India will secure the 
status with in the world’s Top Ten pharmaceutical industries. India 
has relatively a larger manpower having access to Scientific & 
Technical training.  Indigenous Companies like Ranbaxy and Dr.  
Reddy’s Lab. have acquired outstanding and respectable status in 
the World’s pharmaceutical industry.  
8) Capital investment in Indian Pharma Industries has increased by 
nearly 18 times during the period from 1965 to1990s. (At present it  
exceed Rs. 30, 000crores.) In 1965, Ind ia produced only 1500 drug 
formulations; now the number has gone above 1 ½ lakh. After  
implementing economic reforms and joining WTO; India’s 
pharmaceutical business has miracu lously prospered. In 60s, India 
produced only 188 bulk drugs but by the end of 90s, Ind ia produces 
about 40 block busters and bulk drugs. The cost of bulk drugs per 
unit in India is far less than that of advanced economies. Due to the 
Competitive price / quality advantage, Ind ia has captured very 
large markets abroad during the last 1 and 1/2 decades. In 1960s 
India used to earn a fair ly sum of Rs.3 cores by exports; by the end  
of 90s, the amount increased by about 2000 times being Rs.6631 
cores and in the recent year i.e.,2004-5; India earned U.S. $ 3 
billion ( 300 cores dollars) which is equivalent of Rs.15000 cores.  
9) The Indian subsidiaries of Giant Pharma MNCs like Bayer, Parke-
Davi’s,  Glaxo, Ciba-Geigy, Pfizer, Procter & Gamble, Godrej,  
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Phillips,  Aventis, Novaritis,  Johnson & Johnson, Lupin, Merck, 
Solvay farm, Cipla, Torrent pharm, Wockhart etc. have brought 
world class research, patents, techniques which have rad ically 
improved the status of Indian pharmaceutical industry within the 
entire global market of pharmaceuticals.  
10) Along with these foreign giants, purely Indian enterprise 
Companies like Ranbaxy, Dr. Reddy’s Lab, Alembic, Dabur, 
Zandu, J B Chem., J k pharma. Ambalal Surabhai, N. Piramal,  
Aurobindo pharm, Kerala Aayurved ic, Amurtanjan, Himalaya, M 
cure etc. Companies have also made tremendour and equitable 
progress during last 20 years.  
10)  The impact of WTO on trading in pharma products therefore has 
been very very favorable rather than a threatening one! The ‘n’ 
number of opportunities of extending pharma products market all 
over the world; opened up to boost up India’s export earnings. On 
the other hand, the process cost of medicines in domestic market 
did not rise by 15 to 30 times; as was pred icted by experts, opinion 
makers, political critics of WTO & U.S. Lobby. The prices of 
Indian Medicines have remained reasonable & affordable to the 
common man; because nearly 90% of Indian pharma products are 
generic; and remain unaffected by ‘Global patent r ight’.  
11) There is a remarkable cost-difference of production of standard 
Medicines between U.S. & India. There is again a vast difference 
between prices of Global Brand medicines and Indian generic 
substitutes. E.g. Prisolec Brand in U.S. cost $3.7 per tablet;  
whereas its Indian generic substitute viz omeprazole hardly costs 
about $ 0.09 ( or Rs. 4.50 as against Rs.180 ) Prozac Brand in U.S. 
costs $ 2.2 whereas its Ind ian generic ‘Fluoxetine’ costs only 0.6 
dollar in India i.e.  about Rs.30 as against Rs.100 rupees in U.S. 
Ranitidine antacid tablet manufactured by glaxo in India cost only 
one rupee whereas its counterpart in U.S. ‘Zantac’ costs about 
Rs.80 in terms of Indian rupees. Simvastatine ( Rnbaxy’s generic ) 
in India costs only about Rs.10per tab. Which in U.S. costs about 
US 20.7 dollars. (Rs.100) The statistical evidence clearly proves 
that Indian drug prices remained comparatively cheaper in spite of 
the acceptance of the WTO regime. In fact, Indian pharmaceutica l 
industry; due to globalization, liberalization & WTO regime has 
improved tremendously so much so, that it  has gained a ‘real take-
off position’ in the galaxy of world class pharmaceutical industries 
of the world. The estimated projections reveal that India has bright 
prospects to earn the prestigious rank among Word’s Top Fifteen 
countries, as far as, pharmaceutical businesses concerned.  
These finding cu lminate to form a principal conclusion that ‘The impact 
of WTO brought strength, progress and opportunities of prosperity to 
Indian pharmaceutical trade rather than creating problems and threats.’  
The impact, no doubt created challenges of upgrading the Technology and  
competition of upholding essential quality and the word class acceptance; 
but these challenges too worked as disgu ised boons! 
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